🇺🇸 Protagonist Therapeutics, Inc.
Forum topic · PTGX · Company page: financials, ownership and filings
Join the discussion on Protagonist Therapeutics, Inc.
Loading…
Results announced on 5 November 2026
Protagonist Therapeutics, Inc. announced results on 5 November 2026 (SEC Form 8-K, item 2.02).
For the quarter ended 30 September 2026: revenue of $274 million (up 5726% from a year earlier) and net income of $220 million.
Mutual funds: 321 funds hold $4.0 billion
321 mutual funds in 2 countries hold shares of Protagonist Therapeutics, Inc. worth $4.0 billion, about 49.7% of the company (funds' newest reports, up to 31 July 2026).
Since their previous reports 177 funds added shares and 122 sold; on balance they bought $377 million. Share splits are not counted as trading.
Source: Automatic updates: SEC filings, regulators' notices and fund reports held on this site. Posts marked 🤖 are written automatically from official data and state no opinion. Member comments are their authors' views, shown after an editor's review; they are not investment advice.